Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150

1 hour ago 1

Joel South

Thu, March 12, 2026 astatine 10:14 AM CDT 4 min read

Wells Fargo raised its Merck terms people to $150, betting that sac-TMT’s imaginable to displace chemotherapy crossed aggregate crab indications, combined with KEYTRUDA’s continued maturation and a deepening pipeline of 80 Phase 3 studies, volition thrust a pipeline-driven rerating done 2026.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks. Get them present FREE.

Merck & Co., Inc. (NYSE:MRK) has been connected a beardown betterment run, gaining 23% implicit the past twelvemonth and 8% year-to-date, though the banal has pulled backmost some, present good beneath its 52-week precocious of $125.14. Most analysts clasp measured views, with Street statement sitting astatine $127.22. But Wells Fargo sees considerably much upside, raising its terms people to $150 from $135 with an Overweight rating, implying meaningful upside from existent levels. That people stands good supra the Street average. But tin MRK realistically scope $150 by the extremity of 2026?

Wells Fargo's bull lawsuit centers connected sacituzumab tirumotecan, oregon sac-TMT, Merck's investigational anti-TROP2 antibody-drug conjugate. The steadfast believes sac-TMT could go the best-in-class TROP2 ADC and regenerate chemotherapy crossed aggregate lung, breast, and gynecologic crab indications. That thesis gets tangible enactment from the FDA, which awarded sac-TMT a Commissioner's National Priority Voucher, and from a strategical financing statement with Blackstone Life Sciences to partially money sac-TMT development.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

Sac-TMT pipeline value: Sac-TMT's imaginable to displace chemo successful lung, breast, and gynecologic cancers represents a multi-indication commercialized accidental that could meaningfully grow Merck's oncology franchise good into the adjacent decade, representing a multi-indication commercialized accidental that could meaningfully grow Merck's oncology franchise good into the adjacent decade.
KEYTRUDA's continued expansion: The flagship immunotherapy posted $8.337 cardinal successful Q4 2025 revenue, up 6% year-over-year, with the FDA besides accepting 2 sBLAs for KEYTRUDA positive Trodelvy successful first-line PD-L1+ metastatic triple-negative bosom cancer. Expanding indications widen KEYTRUDA's gross runway contempt the 2028 patent cliff.
Emerging maturation portfolio: WINREVAIR, Merck's pulmonary arterial hypertension treatment, delivered $467 cardinal successful Q4 2025, up 133% year-over-year, portion a committedness of much than $70 cardinal successful U.S. superior and R&D spending signals management's condemnation successful semipermanent compounding powerfulness for shareholders.